Skip to Main Content

Acadia Pharmaceuticals is purchasing a small Texas startup, CerSci, for $52 million in order to acquire a pain drug in the early stages of development, the company said Tuesday.

If the drug succeeds, CerSci could receive an additional $887 million in payments for hitting commercial and development milestones.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!